Merck & Co., Inc.

🇺🇸New York Stock Exchange
Back to all articles
Merck & Co., Inc. stock analysis MRK overview
Somewhat Bullish +45

Merck (MRK) Stock Could Be 11% Undervalued After June Pipeline Wins - simplywall.st

📈 Merck trades at US$115.48, offering an 11% discount to analyst targets and a 46% gap below a fair value estimate of US$129.74.

✅ Recent June 2026 milestones include FDA approvals for KEYTRUDA plus WELIREG and CAPVAXIVE, plus Phase 3 success for tulisokibart.

📉 Short-term share price is down 5.66% in the last 30 days despite longer-term YTD gains of 8.48% and one-year TSR of 48.88%.

💰 The company's pipeline has nearly tripled since 2021 with a potential commercial opportunity over US$50 billion by the mid-2030s.

🚀 Strong launches of WINREVAIR and CAPVAXIVE are currently driving revenue growth and supporting future expansion.

⚠️ KEYTRUDA faces eventual loss of exclusivity, which could challenge the long-term undervaluation narrative.

📉 GARDASIL sales are experiencing softness in the Chinese market, posing a specific regional revenue risk.

💸 Valuation is elevated with a P/E ratio of 31.9x compared to an industry average of 14.9x and peers at 25x.

📊 The current P/E of 31.9x is only slightly below a fair ratio of 33.5x, suggesting limited room for multiple expansion.

🔍 Analysts question whether the market has already fully priced in the future growth implied by the high valuation multiples.

Bullish Signals
  • Merck's stock is trading at an 11% discount to the average analyst price target and a 46% gap below one intrinsic value estimate of US$129.74.
  • The company has nearly tripled its late-phase pipeline since 2021, creating a potential commercial opportunity exceeding US$50 billion by the mid-2030s.
  • Recent FDA approvals for KEYTRUDA plus WELIREG and CAPVAXIVE, along with Phase 3 success for tulisokibart, demonstrate strong pipeline momentum.
  • Ongoing strong launches of key new products like WINREVAIR and CAPVAXIVE are positively impacting current revenues.
  • Longer-term momentum remains robust with a one-year total shareholder return of 48.88% despite recent short-term volatility.
Risk Factors
  • Merck's share price has declined by 5.66% over the last 30 days, indicating recent negative market reaction.
  • KEYTRUDA faces an eventual loss of exclusivity, which poses a significant long-term revenue risk to the undervaluation thesis.
  • The stock trades at a P/E ratio of 31.9x, which is significantly higher than the US Pharmaceuticals industry average of 14.9x and peer average of 25x.
  • The current valuation suggests limited 'valuation slack' as the P/E is only slightly below a fair ratio of 33.5x.
Full Analysis
Merck (MRK) stock is currently trading at US$115.48, which represents an 11% discount to the average analyst price target and a 46% gap below one intrinsic value estimate of US$129.74. The article highlights recent positive developments in June 2026, including new FDA approvals for KEYTRUDA plus WELIREG and CAPVAXIVE, as well as Phase 3 success for the ulcerative colitis drug tulisokibart. Despite these pipeline wins, Merck's share price has declined by 5.66% over the last 30 days, though longer-term momentum remains strong with a year-to-date return of 8.48% and a one-year total shareholder return of 48.88%. The company's acquisition and licensing strategy has nearly tripled its late-phase pipeline since 2021, creating a potential commercial opportunity exceeding US$50 billion by the mid-2030s. Key drivers for the bullish narrative include ongoing strong launches of products like WINREVAIR and CAPVAXIVE, which are positively impacting revenues. However, valuation concerns persist as Merck trades at a P/E ratio of 31.9x, significantly higher than the US Pharmaceuticals industry average of 14.9x and peer average of 25x, suggesting limited valuation slack despite the fair value premium. Investors must weigh the potential for earnings growth against specific risks, including KEYTRUDA's eventual loss of exclusivity and softness in GARDASIL sales within China. The article concludes that while the stock appears undervalued based on fundamental models, the high multiple implies the market may already be pricing in much of the future growth.